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RVR, SVR12 and SVR24 than placebo. There was no difference in the safety of sofos-
buvir and placebo groups for the majority of evaluated outcomes. ConClusions: 
Our meta-analysis indicates promising efficacy and a good safety profile of sime-
previr for both evaluated doses. Data concerning sofosbuvir reveal the benefits of 
this drug in hepatitis C virus genotype 1 treatment, also in safety terms.
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introduCtion: the probability of occurrence of virological failure in patients 
diagnosed with HIV in ARV drug treatment of first and second line is 0.15 and 0.46 
respectively, produce the emergence of viral resistance, loss of future schemes, 
increased hospital admissions, disease progression and death. objeCtives: To 
determine the associated factors that explain the virological success and the time 
needed to reach it. Methods: Type of study: retrospective cohort survival analysis. 
Type of patients: belonging to EPS|SURA regional Medellin, diagnosed with HIV and 
exposed to first time antiretroviral therapy. Variables: dependents (virologic suc-
cess and time required to reach it) and independents (sociodemographic, clinical 
and pharmacotherapeutic). Analysis:frequencies, summary measures, and Kaplan 
Meier for the univariate stage, chi square, Student’s t test or Mann-Whitney U 
and Log Rank Test for the bivariate phase, proportional hazards model and mul-
tiple logistic regression in multivariate phase. results: 97% of patients achieved 
virologic success, needed 209 days (SD±10.14). Patients had a 95% probability of 
achieving virological success in the first 8.5 months. Properly use drugs was asso-
ciated with a shorter time to achieve virologic success HR 2.68 [1.22-5.90] and a 
greater number of problems with drugs was associated with a longer time HR 0.60 
[0.43-0.83]. ConClusions: virological success was higher than the studies found, 
which was obtained in a short time and was maintained throughout the observation 
period. The variables in this study were not associated with virologic success but 
were associated with a shorter time to reach it.
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objeCtivos: Estudiar la evolución del consumo de antibacterianos de uso restrin-
gido en pacientes adultos hospitalizados durante el periodo 2005 al 2012, en el 
hospital Las Higueras de Talcahuano. MetodologíAs: Se realizó un estudio ret-
rospectivo durante los años 2005 - 2012, del consumo mensual de antibacterianos 
de uso restringido. Los antibacterianos considerados fueron clasificados según el 
sistema ATC/DDD. Se incluyo vancomicina, carbapenémicos (imipenem, ertapenem 
y meropenem) y cefalosporinas de tercera generación (ceftriaxona, ceftazidima y 
cefotaxima). Se determinó la densidad de consumo expresado en porcentaje y en 
términos del número de DDD/100 días-cama-ocupados. La evolución del consumo 
se determinó calculando diferencia porcentual entre los año 2005 y 2012. La com-
paración de los consumos se realizó con la prueba t-test. Se consideró diferencias 
significativas con un nivel de significancia de p< 0.05. resultAdos: Ceftriaxona 
fue el antibacteriano con mayor consumo total (63%) (292,4 DDD/100 días-cama-
ocupados) seguido por vancomicina (17%) (77,13 DDD/100 días-cama-ocupados). 
Por su parte, el servicio de paciente crítico y de cirugía mostraron el mayor con-
sumo de antibióticos, con un total de 150 DDD/100 días-cama-ocupados (54%) y 54 
DDD/100 días-cama-ocupados (20%) respectivamente. En relación a la evolución del 
consumo, se observó un incremento significativo en el consumo de vancomicina 
(+67%; p< 0,05), imipenem (+62%; p= 0.004), meropenem (+84%; p= 0.006) y ceftri-
axona (+44%; p= < 0.05). ConClusiones: El consumo de todos los antibióticos 
estudiados aumento significativamente, especialmente ceftriaxona, vancomicina 
y carbapenémicos. La consecuencia de este consumo pudiera significar un aumento 
de la resistencia bacteriana intrahospitalaria y los costos asociados en la atención 
de salud, por lo que se sugiere su estudio.
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bACkground: It is World Health Organization’s Global Plan to eradicate Tuberculosis 
(TB) disease by the year of 2050, but it is difficult to achieve that goal by the current 
rate of infection decrease. Our goal is to evaluate whether calcium channel blocker, 
an existing cardiovascular drug can affect the onset of active TB. objeCtives: To 
evaluate whether the use of different classes of calcium channel blockers (CCBs) affect 
the risk of incident active tuberculosis disease. Methods: A nested case control 
study was carried out using the claims data from National Health Insurance Research 
Database of Taiwan between January 1997 and December 2011. Index date referred to 
the first date of TB diagnosis. Patients with CCBs exposure were defined by receiving ≧ 
7 days of prescription ending in 3 different time frames. Current use refers to prescrip-
tion that ended within 30 days of the index date. Multivariate regression and a disease 
risk score (DRS) technique were used to calculate risk of active TB disease. results: 
INFectIoN – clinical outcomes studies
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objeCtives: To assess malaria diagnosis and treatment practices follow-
ing introduction of rapid diagnostic test in Adama district health posts, central 
Ethiopia. Methods: A Cross-sectional study was conducted from January 24 to 
February 9, 2014 among febrile patients, and caretaking health workers to determine 
the perceptions and practices related to rapid diagnostic tests (RDTs). Moreover, the 
treatments prescribed were assessed at the selected Health posts. From the total of 
37 health posts in Adama district, 10 health posts were selected by simple random 
sampling technique. All the patients who visited the health posts during the study 
period and all health service providers working in the selected health posts were 
included in the study. results: The survey was undertaken at ten health posts 
which use RDT for parasitological confirmation. Twenty health workers and 104 
patients were interviewed at health posts. Eighty three patients (79.8%) were seen in 
health posts with available parasite based diagnostic test (i.e. RDT)) and 21(20.2%) in 
facilities without RDT. The overall malaria positivity rate was 48(57.8%). Anti–malaria 
drugs were prescribed to all 48(100%) patients with positive RDT and to 19(54.3%) of 
RDT negative patients. Among non-tested patients, anti-malaria drugs were given 
to 12(57.1%), with a higher prescription rate in health posts without RDTs results. 
Among 104 patients presenting with fever or history of fever, 64(61.5%) were pre-
scribed with antibiotics and anti-pain. ConClusions: Findings from this study 
show that over prescription with anti-malarial drugs is common in Adama district 
health posts. The use of rapid malaria diagnostics was also associated with higher 
prescription of antibiotics among patients with negative test results. The Adama 
district health office should provide on job and other capacity building trainings for 
health workers on RDTs, the diagnosis and management of other causes of fever 
and the importance of adhering to test results.
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objeCtives: To assess the effect of human leukocyte transfer factor for paren-
teral use (TF) in adult and pediatric patients suffering from cellular immunode-
ficiency (CID) in whom TF had been indicated for treatment of respiratory and/
or urinary tract infections, prostatitis and/or vulvovaginitis episodes. Methods: 
Observational multicenter retrospective study in subjects being treated with TF in 
the period from September 2012 to April 2013 in Slovakia. The primary objective 
was to evaluate the effectiveness by assessment of the number of documented 
infections over one year since the treatment began as compared to the last year 
of the pre-treatment period. Moreover, the resource use and QoL assessment was 
conducted using EQ-5D. results: The sample (98 analyzed patients) in 9 centers 
was predominantly female (75.5%) and the average age was 46.6, with a range of 
7 to 82. The most common recurrent episodes were respiratory tract infections 
occurring 5 (472/96 with infection) times at average in the year before TF initia-
tion (96 patients), followed by urinary tract infections (n= 38) and vulvovaginitis 
episodes. The significant reduction was observed in all three types of recurrent 
infections after treatment with TF (prostatitis not analyzed). Respiratory tract infec-
tions where reduced from 5 to 2 a year after, in contrast to the period before initia-
tion of TF application (p< 0.001). Significant reduction was achieved in urinary tract 
infections and vulvovaginitis episodes (p< 0.001). Reduction was accompanied by a 
lower resource use, measured by the need of antibiotics and hospitalizations. The 
median of parenteral TF doses was 8 injections for a full study period (maximum 
2 years). ConClusions: The conducted study showed that leukocyte human TF 
helps to reduce recurrence of episodes of infections in adult and pediatric patient 
with CID. Besides clinical and resource outcomes, the contribution of this study is 
the elicitation of utility values for CID of different severity.
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objeCtives: To evaluate the efficacy and safety of the second-wave direct-act-
ing antivirals simeprevir and sofosbuvir in patients with HCV genotype 1 infec-
tion through a systematic review and meta-analysis of randomized clinical trials 
(RCTs). Methods: Electronic searches were performed in databases MEDLINE, 
International Pharmaceutical Abstracts (IPA), Cochrane Library, SCIELO and Scopus. 
Statistical analyses were executed using the software Review Manager version 
5.3. results: 774 articles were identified, of which 10 RCTs were selected for data 
extraction and statistical analysis. Simeprevir 100 mg promoted better RVR and 
SVR24 Resultsthan placebo, and simeprevir 150 mg was superior to placebo for the 
following outcomes: RVR, SVR12, SVR24, SVR12 rates according to METAVIR score 
for the subgroups F0-F2, F3 and F4, SVR12 rates according to HCV genotype for both 
genotype 1a and genotype 1b, SVR12 rates for HCV genotype 1a without baseline 
Q80K and SVR12 according to IL28B genotype for CC, CT and TT. More viral relapse 
events were observed in the placebo group, for both evaluated doses. There were no 
significant differences for all of the evaluated safety outcomes between the sime-
previr 100 mg and the placebo groups, and for almost all evaluated safety outcomes 
between the simeprevir 150 mg and placebo groups. Sofosbuvir promoted better 
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0,9% saline on the costs of IV fluids and costs associated with fluid-related complica-
tions. The target population was adult patients (age ≥ 18 years) meeting SIRS criteria 
and receiving solely crystalloid IV fluids. The interventions compared were: patients 
mainly receiving BAL fluid mix versus patients receiving IV fluid therapy without 
BAL fluid mix considering an increasing adoption rate over 5-year period. results: 
The base case was defined as a 300-bed hospital with 90% occupancy, a 2.7% SIRS 
frequency among inpatients, current BAL adoption level of 2%, projected year 5 BAL 
adoption levels of 20%. The patient number per month requiring fluid resuscitation 
calculated was 47 (564 per year). The overall savings were calculated by subtract-
ing the costs of complications and treatments associated with BAL adoption level 
for a given year from costs associated with current BAL adoption level and adding 
the incremental costs. The 72-hour fluid cost increased from R$ 1.480 (year 1) to R$ 
3.552 (year 5). The cumulative hospital savings versus current usage were estimated 
to be R$ 98.737 by year 1 and ~R$ 1.6 M by year 5. At the pharmacy level estimated 
total cumulative savings were R$ 11.577 in the first year and R$ 194.866 over the 5 
year period. ConClusions: Despite the incremental cost on fluid therapy, increased 
usage of BAL in SIRS patients versus current BAL usage was demonstrated to be a 
cost saving strategy for the hospital and consequently for the healthcare system.
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objeCtivos: La incidencia infecciones de piel y tejidos blandos producidas por S. 
aureus meticilino resistente (SARM) ha aumentado en los últimos años, para su 
tratamiento se recomienda el uso de antibióticos de amplio espectro con cobertura 
de SARM como linezolid y vancomicina. El objetivo de este estudio es determinar 
el costo asociado al uso de vancomicina IV monoterapia vs cambio temprano a 
linezolid oral en el tratamiento de infecciones de piel y tejidos blandos en institu-
ciones de salud privadas en Chile MetodologíAs: Se realizó un modelo de esti-
mación de costos para determinar el diferencial al realizar el cambio de terapia IV 
a oral por persona. Los comparadores incluidos fueron vancomicina (1gr c/12hr) 
y linezolid oral (600 mg BID) La perspectiva del análisis fue la de las instituciones 
Privadas de Salud (ISAPREs) en Chile. Los costos directos incluidos corresponden a 
los medicamentos en comparación y a la estancia hospitalaria durante la adminis-
tración del medicamento IV; fueron obtenidos de aranceles oficiales para la estancia 
hospitalaria y del reporte del canal privado para los medicamentos. El horizonte 
de tiempo del análisis fue 14 días resultAdos: Los costos directos asociados 
a vancomicina IV (monoterapia) durante 14 días fueron $2.765.000 por paciente, 
al realizar el cambio de vancomicina IV a linezolid oral los costos variaron entre 
$2.643.500 y $1.428.500 al realizar el cambio entre el día 13 al día 3, respectivamente. 
Al realizar el cambio de terapia IV a oral, se liberaría la disponibilidad de días-cama 
en las instituciones (costo de oportunidad) ConClusiones: Al realizar el cambio de 
vancomicina IV a linezolid oral se generaría un ahorro de 4% a 48% en comparación 
con la monoterapia de vancomicina, el costo de oportunidad por tener los pacientes 
con medicación IV son los días-cama que se pueden liberar al realizar el cambio 
temprano de vía de administración IV a oral.
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objeCtivos: Estimar los costos de las Enfermedades Metaxénicas (EMTX) en los 
establecimientos del Ministerio de Salud del Perú. MetodologíAs: Se realizó 
una evaluación económica parcial de tipo costo de enfermedad (CE). La población 
de estudio fue una cohorte hipotética de pacientes con EMTX afiliada al Seguro 
Público de Salud (Seguro Integral de Salud). Los costos se estimaron desde la per-
spectiva del financiador tomados para el año 2014. La definición de los esquemas 
de manejo clínico (procedimientos médicos y medicamentos para prevención, diag-
nóstico, tratamiento y seguimiento de la enfermedad) provienen de las Condiciones 
Asegurables del Plan Esencial de Aseguramiento en Salud (PEAS). Cada esquema 
de manejo clínico se ha estimado con la metodología de costeo estándar. El costo 
total fue ajustado por factores de oferta, demanda y adherencia. resultAdos: 
La cohorte hipotética de EMTX es de 396,592 personas para el año 2014, de las 
cuales 5,434 corresponden a Dengue; 575 a Bartonelosis; 34,371 a Fiebre Amarilla; 
91,982 a Tripanosomiasis; 11,131 a Leishmaniosis; y 253,099 a Malaria; (Incidencia 
de Dengue: 0.05%, Incidencia de Bartonelosis: 0.03%, Incidencia de Fiebre Amarilla: 
0.0004%, Incidencia de Tripanosomiasis: 0.85%, Incidencia de Leishmaniosis: 0.04%, 
Incidencia de Malaria vivax: 0.23%, incidencia de malaria falciparum: 0.01%). El 
costo total para EMTX es de 6,309,054 dólares correspondiendo para Dengue 
320,535 dólares, Bartonelosis 193,488 dólares, Fiebre Amarilla 296,326 dólares, 
Tripanosomiasis 3,142,325 dólares, Leishmaniosis 68,285 dólares y para Malaria es 
de 2,288,096 dólares. El costo total correspondiente a prevención es 2,121,011 dólares 
(33.6%), diagnóstico 1,195,563 dólares (18.9%), tratamiento 1,297,189 dólares (20.6%) 
y para seguimiento 1,695,292 dólares (26.9%). El costo fijo correspondió a 3,387,381 
dólares (53.7%) y el costo variable a 2,921,693 dólares (46.3%). ConClusiones: 
El costo anual total para Enfermedades Metaxénicas se estimó en 6,309,054 
dólares. Este monto representa el 5.8% del presupuesto anual 2014 del Programa 
Presupuestal Enfermedades Metaxénicas y Zoonosis.
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From a cohort of one million patients with 13 years follow-up, 7164 cases of new active 
TB and 716,400 controls were identified. Use of dihydropyridine class of CCBs, but 
not phenylalkylamine and benzothiazepine CCBs were associated with lower risk of 
active TB. Current use of dihydropyridine was associated with lower risk of active TB 
before (0.75 ; 95%CI, 0.69 – 0.82) and after DRS adjustment (0.70 ; 95%CI, 0.64 – 0.77). 
Dose response analysis suggested that longer term use of dihydropyridine can lead 
to even lower risk of active TB. ConClusions: Our novel Resultssuggest that use of 
dihydropyridine class of CCBs decrease the risk of active TB. However, more studies 
are required to validate our Resultsbefore recommending CCBs to cardiovascular 
patients at high risk of TB.
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objeCtives: Current study is aimed to explore and to observe clinical treatment 
outcomes during HAART therapy among HIV/AIDS patients Methods: An observa-
tional retrospective study of all patients diagnosed of HIV infection and on HAART 
therapy from Jan 2007 to Dec 2012 was conducted at infectious disease department 
of Hospital Pulau Pinang, Malaysia. Patient socio-demographic details along with 
clinical features were recorded. Data was descriptively analyzed by using statistical 
package for social sciences (SPSS 20) results: Out of 792 patients that underwent 
HAART therapy, 607 (76.6%) were male and 185 (23.3%) were female patients. The 
treatment outcome of the total study population (792) on the basis of recovery of 
CD4 cells count to the normal range was (≥ 350 cells/mm3). Out of total patients 
(792), 645 (81.4%) patients improved their CD4 cells count under the treatment of 
HAART therapy out of which 488 (61.6%) male and 157 (19.8%) female patients were 
improved to a normal range of CD4 cells count. On binary logistic regression both 
Malay (OR 2.32, p < 0.001) and Chinese patients (OR 0.37, p < 0.001) were found to be 
statistically significant. Patients having age less than 30 years (OR 0.58, p 0.09), with 
secondary education level (OR 0.44, p 0.001), and Graduate patients (OR 0.50, p 0.09) 
were also have a signification association with treatment outcomes. Non-smokers 
(OR 2.16, p 0.001), non-alcoholic (OR 1.42, p 0.05) and non-drug abusers were also 
found to be statistically significant ConClusions: The study indicates the clinical 
treatment outcomes in non-smokers, non-alcoholics and non-drug abusers HIV 
patients were higher. Also indicate a significant treatment outcomes on educated 
patients which may be due to the awareness about the infection. However, a mul-
ticenter study with a large sample size may provide us with better understanding 
of this relationship
INFectIoN – cost studies
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dAclAtAsVIr+AsuNAPreVIr eN el trAtAmIeNto de PAcIeNtes coN 
hePAtItIs c eN colomBIA
Romero Prada ME, Marrugo Figueroa RD, Acero Acero G, Alfonso Quiñones PA
Fundación Salutia, Bogotá, Colombia
objeCtivos: Estimar el impacto per cápita año a año de la utilización de 
daclatasvir+asunaprevir en pacientes con hepatitis C, frente tratamien-
tos convencionales, en el sistema de salud Colombiano. MetodologíAs: 
A partir de un modelo de costo-utilidad que demuestra la dominancia de 
daclatasvir+asunaprevir(D/A) en el tratamiento de pacientes con hepatitis C, sobre 
peginterferon alfa+ribavirina, más telaprevir o boceprevir, se realizó un análisis 
de impacto presupuestal para un quinquenio, considerando costos directos en 
salud, desde la perspectiva de un tercer pagador. Los costos de servicios fueron 
extraídos de bases de datos de aseguradores colombianos, las frecuencias de uso 
fueron calculadas mediante opinión de expertos. Los costos de medicamentos, 
se estimaron con base en el Sistema de Información de Precios de Medicamentos 
de Colombia. Se analizaron dos escenarios, en el actual el 100% de los pacientes 
son tratados con telaprevir+A/R o boceprevir+A/R; mientras en el escenario nuevo 
se trabaja con tasas de reemplazo del 30% y 50% de uso de D/A. resultAdos: 
Dado un estimado de 1.500 pacientes que pueden ser objeto de la tecnología, el 
impacto presupuestal a tasas de reemplazo del tratamiento actual del 30 y 50% 
por (D/A) para el primer año, sería de $3.300.602.149 y $5.501.003.583, respectiva-
mente. No obstante, a partir del segundo año y hasta el quinto año la inclusión de 
D/A, genera un ahorro acumulado de $925.729.468 y $1.542.882.448, bajo tasas del 
30 y 50% de reemplazo respectivamente. De esta manera, el impacto per cápita 
acumulado al quinto año es de $49,48 y $82,46 pesos, bajo tasas del 30 y 50% de 
reemplazo ConClusiones: A partir del segundo año de la inclusión de D/A se 
comienzan a generar ahorros por la tecnología, alcanzando al quinto año un gasto 
per cápita no mayor de $49,48 y $82,46 dependiendo del porcentaje de pacientes 
que se tengan en el medicamento.
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objeCtives: The study aimed to assess the economic implications of increasing 
usage of calcium free balanced solutions (BAL) for IV fluid therapy on costs of fluids 
and avoidance of fluid-related adverse outcomes in SIRS patients from a Brazilian 
hospital perspective. Methods: An Excel®-based budget impact model (BIM) was 
developed to assess the impact of increased usage of BAL fluids in SIRS patients versus 
